close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

40.59 -0.50 (-1.22%)
Delayed Quote Updated: 12:10 PM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
News headline image
Novo Nordisk Defends Semaglutide Alzheimer’s Trials After Studies Miss Goals ↗
A Novo Nordisk executive outlined the scientific rationale behind testing Semaglutide in Alzheimer’s disease at a meeting on Tuesday. 
Via Stocktwits
News headline image
The Shifting Tides: How Retail and Institutional Forces Reshape Market Dynamics
As of late 2025, the financial markets are in the midst of a profound transformation, driven by the dynamic and often divergent interplay between institutional behemoths and an increasingly empowered... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
News headline image
Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture
Artificial intelligence, often spotlighted for its advancements in mainstream applications like conversational agents and autonomous vehicles, is quietly orchestrating a profound transformation across... 
Via TokenRing AI
Topics Artificial Intelligence Economy Emissions
Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study ↗
Via Stocktwits
News headline image
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call ↗
Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion. 
Via Stocktwits
Topics Intellectual Property
News headline image
Eli Lilly Cuts Prices For Weight Loss Drug Zepbound To $299 A Month As It Takes On Novo Nordisk’s Wegovy ↗
Patients can buy Zepbound at these prices through the company’s direct-to-consumer platform, LillyDirect. 
Via Stocktwits
Topics Economy Government
News headline image
Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know. ↗
A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity? 
Via The Motley Fool
News headline image
This 7% Yielder Could Be a Top AI Play ↗
One drug developer could be on the cusp of AI-powered glory. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Novo Nordisk Stock Tumbles: HSBC Downgrades After ‘Lottery Ticket’ Alzheimer’s Bet Fails, But Retail Traders Call Selloff ‘Ridiculous’ ↗
Via Stocktwits
News headline image
Why Novo Nordisk Stock Just Hit a 4-Year Low ↗
Novo Nordisk's drug trial failure is the latest in a series of 2025 woes for the company. 
Via The Motley Fool
News headline image
Novo Nordisk A/S (NYSE:NVO) Offers a Strong Dividend and Sound Fundamentals ↗
Novo Nordisk (NVO) is a top dividend stock with a 3.71% yield, strong earnings, and a history of reliable dividend growth, offering dependable income. 
Via Chartmill
News headline image
Novo Nordisk Stock Investors Get Huge News on Drug Trial Results ↗
Investors will want to see these key developments concerning Novo Nordisk's pipeline of new treatments. 
Via The Motley Fool
News headline image
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 ↗
The mid-cap biotech could become a notable player in the industry's hottest therapeutic area. 
Via The Motley Fool
News headline image
Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗
Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries. 
Via Stocktwits
Topics ETFs
News headline image
JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets ↗
JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season. 
Via Stocktwits
Topics Economy Government
News headline image
Why Novo Nordisk Stock Is Moving Higher Today ↗
Patients could soon access higher-dose injections. 
Via The Motley Fool
Topics Stocks
News headline image
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗
Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA. 
Via Investor's Business Daily
Topics Economy Government
News headline image
Did Pfizer Just Say "Checkmate" to Novo Nordisk? ↗
The weight loss drug market may approach almost $100 billion by the end of the decade. 
Via The Motley Fool
News headline image
Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗
Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector. 
Via Stocktwits
News headline image
Here's Why Novo Nordisk Stock Popped Today ↗
Good news from a GLP-1 receptor agonist clinical trial hit the market today. 
Via The Motley Fool
News headline image
Novo Nordisk (NYSE:NVO) Presents a Compelling Case for Value Investors ↗
Discover Novo Nordisk (NVO), a potentially undervalued stock with strong profitability, solid financial health, and a good dividend yield. 
Via Chartmill
News headline image
Why Novo Nordisk Stock Sank 5.6% Today ↗
Semaglutide was no better than a placebo. 
Via The Motley Fool
Topics Stocks
News headline image
Hims, Block, and NRG Just Launched Huge Stock Buybacks ↗
Via MarketBeat
News headline image
Biggest Stock Movers Today, Nov. 24: AVGO, NVO, & More ↗
Stocks were up sharply to start the holiday week. 
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
News headline image
Wondering what's happening in today's pre-market session? ↗
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies ↗
The company said that it is discontinuing the trials. 
Via Stocktwits
News headline image
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant? ↗
The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back. 
Via The Motley Fool
Topics Government
News headline image
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026? ↗
Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon. 
Via The Motley Fool
News headline image
3 Top Dividend Stocks to Buy in November ↗
November is a great month to be thankful for opportunities to invest in these fantastic companies. 
Via The Motley Fool
Topics Bonds Economy
News headline image
Big News for Novo Nordisk Stock Investors ↗
Millions of people in the world are overweight, and Novo Nordisk hopes to capture a growing share of this lucrative treatment opportunity. 
Via The Motley Fool
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.